Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Colorectal Neoplasms × pertuzumab × Clear all

Phase

Status

Sponsor Class

OTHER 2 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 60 HER2-positive Breast Cancer 10 Neoplasm Metastasis 5 Ovarian Neoplasms 4 Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Stomach Neoplasms 3 Solid Tumor 2 Prostatic Neoplasms 2 Endometrial Neoplasms 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Urinary Bladder Neoplasms 1 Solid Tumors 1 Solid Cancers 1 Solid Cancer 1 Resectable HER2-positive Breast Cancer 1 Recurrence 1 Patient Preference 1 Neoplasms, Unknown Primary 1 Lung Neoplasms 1 Liver Neoplasms 1 Inflammatory Breast Neoplasms 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 HER2-Positive Early Breast Cancer 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Early-stage or Locally Advanced HER2-positive Breast Cancer 1 Early or Locally Advanced HER2-positive Breast Cancer 1

Interventions

Bevacizumab 186 Fluorouracil 148 Leucovorin 132 Cetuximab 125 Irinotecan 113 Oxaliplatin 107 pembrolizumab 96 Capecitabine 81 IFL protocol 53 regorafenib 42 Panitumumab 42 Nivolumab 42 Folfox protocol 39 Gemcitabine 30 trifluridine tipiracil drug combination 27 Cisplatin 24 Carboplatin 24 atezolizumab 22 Paclitaxel 20 Drug Therapy 20 Pemetrexed 19 130-nm albumin-bound paclitaxel 17 Trastuzumab 14 encorafenib 13 Ipilimumab 13 HMPL-013 13 tislelizumab 12 Trifluridine 12 spartalizumab 11 Docetaxel 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02291289 2024-05-06

MODUL

Hoffmann-La Roche

Phase 2 Completed

1,044 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡